Published on 10 May 2024 on Simply Wall St. via Yahoo Finance
Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target...
It's been a good week for AbCellera Biologics Inc. (NASDAQ:ABCL) shareholders, because the company has just released its latest first-quarter results, and the shares gained 2.6% to US$3.95. It was a moderately negative result overall - revenue fell 9.6% short of analyst estimates at US$10.0m, although at least statutory losses were marginally smaller than expected, at US$0.14 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
View our latest analysis for AbCellera Biologics
